Ted Nark Biography and Net Worth

Director of Amneal Pharmaceuticals

Ted Nark has served as Managing Director of KRG Capital Partners, a Denver-based private equity fund currently investing a $2 billion fund, since 2007. In that role, Mr. Nark has led the identification, negotiation and due diligence of new acquisitions and has worked with portfolio companies and maintained relationships with limited partners. While at KRG, Mr. Nark has led the acquisition and successful monetization of companies including Convergint Technologies, Diversified Food Services and Petrochoice. From 2006 to 2007, Mr. Nark was a Partner at Leonard Green & Partners and from 2002 to 2006, he served as Chief Executive Officer and Chairman of the Board of White Cap Construction Supply, a Leonard Green-owned distributor of construction hardware, tools and materials to professional contractors in the United States. Previously, Mr. Nark served as Chief Executive Officer of Corporate Express Australia and Group President at Corporate Express Inc. Mr. Nark currently serves on the Board of Directors of Convergint Technologies, Western Windows, Trafficware, and The Maroon Group. Mr. Nark has previously served on the Boards of Corporate Express Australia, Fort Dearborn, White Cap Construction Supply, FTD, Leslies Pools, Gaiam, Real Goods Solar and Claim Jumper. Mr. Nark received a B.S. from Washington State University.

What is Ted C. Nark's net worth?: The estimated net worth of Ted C. Nark is at least $3.54 million as of November 17th, 2025. Mr. Nark owns 291,029 shares of Amneal Pharmaceuticals stock worth more than $3,544,733 as of December 7th. This net worth estimate does not reflect any other investments that Mr. Nark may own. Learn More about Ted C. Nark's net worth.
How do I contact Ted C. Nark?: The corporate mailing address for Mr. Nark and other Amneal Pharmaceuticals executives is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. Amneal Pharmaceuticals can also be reached via phone at 908-947-3120 and via email at [email protected]. Learn More on Ted C. Nark's contact information.
Has Ted C. Nark been buying or selling shares of Amneal Pharmaceuticals?: Over the course of the past ninety days, Ted C. Nark has sold $1,172,000.00 in Amneal Pharmaceuticals stock. Most recently, Ted C. Nark sold 50,000 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $11.72, for a transaction totalling $586,000.00. Following the completion of the sale, the director now directly owns 291,029 shares of the company's stock, valued at $3,410,859.88. Learn More on Ted C. Nark's trading history.
Who are Amneal Pharmaceuticals' active insiders?: Amneal Pharmaceuticals' insider roster includes Andrew Boyer (EVP, Chief Commercial Officer – Generics), Jason Daly (SVP), John Kiely (Director), Ted Nark (Director), Chirag Patel (Co-Founder, Co-CEO, President & Director), Gautam Patel (Director), Nikita Shah (EVP), and Joseph Todisco (EVP). Learn More on Amneal Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amneal Pharmaceuticals?: During the last year, insiders at the sold shares 16 times. They sold a total of 6,081,062 shares worth more than $52,198,348.02. The most recent insider tranaction occured on November, 17th when Director Ted C Nark sold 50,000 shares worth more than $586,000.00. Insiders at Amneal Pharmaceuticals own 26.6% of the company. Learn More about insider trades at Amneal Pharmaceuticals.
Information on this page was last updated on 11/17/2025.

Ted C. Nark Insider Trading History at Amneal Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2025	Sell	50,000	$11.72	$586,000.00	291,029
11/17/2025	Sell	50,000	$11.72	$586,000.00	291,029
8/28/2019	Buy	50,000	$2.39	$119,500.00

Ted C. Nark Buying and Selling Activity at Amneal Pharmaceuticals

Amneal Pharmaceuticals Company Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Today's Range

Now: $12.18

$11.90

$12.22

50 Day Range

MA: $11.04

$9.72

$12.59

2 Week Range

Now: $12.18

$6.68

$12.68

Volume

2,363,232 shs

Average Volume

1,696,766 shs

Market Capitalization

$3.83 billion

P/E Ratio

609.30

Dividend Yield

N/A

Beta

1.36